CN102099490A - 抑郁症的谷氨酰胺生物标记 - Google Patents

抑郁症的谷氨酰胺生物标记 Download PDF

Info

Publication number
CN102099490A
CN102099490A CN2009801281847A CN200980128184A CN102099490A CN 102099490 A CN102099490 A CN 102099490A CN 2009801281847 A CN2009801281847 A CN 2009801281847A CN 200980128184 A CN200980128184 A CN 200980128184A CN 102099490 A CN102099490 A CN 102099490A
Authority
CN
China
Prior art keywords
vivo imaging
polypeptide
polynucleotide
compound
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801281847A
Other languages
English (en)
Chinese (zh)
Inventor
P·汉森
D·希斯科克
C·莫里斯
A·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN102099490A publication Critical patent/CN102099490A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801281847A 2008-05-15 2009-05-15 抑郁症的谷氨酰胺生物标记 Pending CN102099490A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808833.8 2008-05-15
GBGB0808833.8A GB0808833D0 (en) 2008-05-15 2008-05-15 Biomarkers for depression
PCT/EP2009/055945 WO2009138501A1 (en) 2008-05-15 2009-05-15 Glutamine biomarkers for depression

Publications (1)

Publication Number Publication Date
CN102099490A true CN102099490A (zh) 2011-06-15

Family

ID=39571407

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801281847A Pending CN102099490A (zh) 2008-05-15 2009-05-15 抑郁症的谷氨酰胺生物标记

Country Status (6)

Country Link
US (1) US20110064659A1 (https=)
EP (1) EP2281068A1 (https=)
JP (1) JP2011523638A (https=)
CN (1) CN102099490A (https=)
GB (1) GB0808833D0 (https=)
WO (1) WO2009138501A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105759065A (zh) * 2016-02-26 2016-07-13 天津桑尼匹克生物科技有限公司 血液代谢标记物的用途及抑郁症检测试剂盒

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808834D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808832D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
AU2012223364A1 (en) * 2011-03-01 2013-09-19 Ge Healthcare Limited Radiolabelled Octreotate analogues as PET tracers
JP7264384B2 (ja) 2019-03-29 2023-04-25 日本たばこ産業株式会社 うつ病の評価を補助するための方法及びうつ病の治療法の効果の評価を補助するための方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータを取得する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247442B1 (en) * 1998-05-12 2007-07-24 Human Genome Sciences, Inc. Antibodies to HHPEN62 polypeptide
JP2006513996A (ja) * 2002-10-24 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
WO2004047727A2 (en) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
WO2008020435A2 (en) * 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
GB0808834D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808832D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERIK ARSTAD ET AL: "Closing in on the AMPA receptor Synthesis and evaluation of 2-acetyl-1-(4′-chlorophenyl)-6-methoxy-7-[11C]methoxy-1,2,3,4-tetrahydroisoquinoline as a potential PET tracer", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
RIKKI N. WATERHOUSE ET AL: "Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo", 《NUCLEAR MEDICINE AND BIOLOGY》 *
黄泳等: "运用PET技术研究头电针治疗抑郁症的机理", 《四川中医》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105759065A (zh) * 2016-02-26 2016-07-13 天津桑尼匹克生物科技有限公司 血液代谢标记物的用途及抑郁症检测试剂盒

Also Published As

Publication number Publication date
WO2009138501A1 (en) 2009-11-19
JP2011523638A (ja) 2011-08-18
EP2281068A1 (en) 2011-02-09
GB0808833D0 (en) 2008-06-18
US20110064659A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
CN102099492A (zh) 抑郁症的生物标记
US8562950B2 (en) GABA biomarkers for depression
JP3422776B2 (ja) 乳癌を診断、監視、病期決定、造影及び治療する新規な方法
CN106434870A (zh) ncRNA及其用途
US20110236897A1 (en) Novel markers for diagnosing brain disease caused by brain injury and use thereof
CN105400868A (zh) 使用miRNA检测体内细胞死亡情况的方法
Hernandez et al. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics
CN101490553A (zh) 用parp抑制剂治疗疾病的方法
CN102099490A (zh) 抑郁症的谷氨酰胺生物标记
WO2012001613A1 (en) COMBINATION OF SIX SNPs FOR DETECTING THE PREDISPOSITION TO NEUROVASCULAR DISEASES
Nishigaki et al. Mitochondrial haplogroup A is a genetic risk factor for atherothrombotic cerebral infarction in Japanese females
Alkelai et al. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family‐based, Arab‐Israeli sample
KR20250172511A (ko) 디지털 pcr을 이용한 암 환자 맞춤형 암 치료 방법
US12612661B2 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
JP2025168380A (ja) 膵がん化学療法における副作用発生リスクの予測を補助する方法
CN113981071A (zh) Csf1r相关基因突变作为诊断cvm的标志物及其应用
Kong et al. Progress and Implications from Genetic Studies of Bipolar Disorder
JP6915804B2 (ja) イリノテカンの治療効果予測方法及びそのためのキット
Lee et al. Early diagnosis of ABCB11 spectrum liver disorders by next generation sequencing
KR102039529B1 (ko) 대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
JP2008538893A (ja) 脂質代謝不全の検出方法、及びそれに使用する検査薬
JP6807094B2 (ja) クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
KR20210105134A (ko) 유두형 신장암의 재발 및 예후 예측용 바이오 마커 및 이의 용도
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
KR20190067570A (ko) 신장암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110615